Remove Drug Development Remove healthcare technology Remove Life Science Remove Meeting
article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

AngelEye Health Announces Series B Funding to Support Company’s Rapid Growth

Healthcare IT Today

SeedtoB invests where technological innovation meets a mission-driven mindset which is what made participation in AngelEye Health’s Series B an attractive opportunity for our firm,” said Eller Kelliher , Partner at SeedtoB. “By Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development.